PICCOLO
20 Dec 2022
Trial Summary
PICCOLO (IMGN853-0419) is a Phase 2 multicenter, open label study designed to evaluate the safety and efficacy of Mirvetuximab Soravtansine in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.
Acronym:
PICCOLO
ACTRN/NCT /ethics:
NCT05041257
Scientific title:
Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers
Sponsor / Cooperative group:
ImmunoGen, Inc.
Trial & Patient Characteristics
| Cancer Type | Gynaecological |
|---|---|
| Trial Type | Treatment |
| Phase | Phase II |
| Age Range | 18 years and older |
| Sex | Female |
| Tumour Stream | - |
| Cancer Stage | Locally Advanced |
| Anticipated Start Date | 2021-08-31 |
| Anticipated End Date | 2024-05-31 |
Participating Hospitals
| Hospital | Burnside Hospital |
|---|---|
| Clinical Trial Coordinator | Diana Caruso |
| dcaruso@bunsidehospital.asn.au | |
| Phone | 08 7074 2353 |
| Principal Investigator | Professor Martin Oehler |
| Recruitment Status | Recruiting |